NMR	0	2
analysis	4	11
of	13	14
site	16	19
-	20	20
specific	21	28
ligand	30	35
binding	37	43
in	45	46
oligomeric	48	57
proteins	59	66
.	67	67

Dynamic	69	75
studies	77	83
on	85	86
the	88	90
interaction	92	102
of	104	105
riboflavin	107	116
synthase	118	125
with	127	130
trifluoromethyl	132	146
-	147	147
substituted	148	158
intermediates	160	172
.	173	173

The	175	177
binding	179	185
of	187	188
small	190	194
ligands	196	202
to	204	205
symmetrical	207	217
oligomeric	219	228
proteins	230	237
may	239	241
lead	243	246
to	248	249
a	251	251
number	253	258
of	260	261
different	263	271
partially	273	281
ligated	283	289
intermediates	291	303
but	305	307
should	309	314
finally	316	322
yield	324	328
a	330	330
symmetrical	332	342
fully	344	348
ligated	350	356
enzyme	358	363
/	364	364
ligand	365	370
complex	372	378
.	379	379

In	381	382
the	384	386
case	388	391
of	393	394
the	396	398
trimeric	400	407
protein	409	415
,	416	416
riboflavin	418	427
synthase	429	436
,	437	437
some	439	442
ligands	444	450
form	452	455
an	457	458
unexpected	460	469
protein	471	477
/	478	478
ligand	479	484
complex	486	492
,	493	493
even	495	498
in	500	501
the	503	505
presence	507	514
of	516	517
a	519	519
large	521	525
excess	527	532
of	534	535
ligand	537	542
.	543	543

Three	545	549
different	551	559
bound	561	565
forms	567	571
were	573	576
observed	578	585
by	587	588
19F	590	592
NMR	594	596
spectroscopy	598	609
,	610	610
and	612	614
Scatchard	616	624
-	625	625
type	626	629
analysis	631	638
suggested	640	648
binding	650	656
sites	658	662
of	664	665
similar	667	673
affinities	675	684
.	685	685

NOESY	687	691
analysis	693	700
of	702	703
the	705	707
kinetic	709	715
network	717	723
revealed	725	732
that	734	737
the	739	741
three	743	747
bound	749	753
states	755	760
exchange	762	769
with	771	774
free	776	779
ligand	781	786
,	787	787
but	789	791
not	793	795
with	797	800
each	802	805
other	807	811
,	812	812
thus	814	817
suggesting	819	828
that	830	833
the	835	837
trimeric	839	846
enzyme	848	853
could	855	859
be	861	862
asymmetrical	864	875
.	876	876

This	878	881
information	883	893
permits	895	901
appropriate	903	913
precautions	915	925
to	927	928
be	930	931
taken	933	937
during	939	944
X	946	946
-	947	947
ray	948	950
structure	952	960
analysis	962	969
of	971	972
riboflavin	974	983
synthase	985	992
,	993	993
which	995	999
is	1001	1002
in	1004	1005
progress	1007	1014
.	1015	1015

Quantitative	1017	1028
analysis	1030	1037
of	1039	1040
the	1042	1044
NOESY	1046	1050
spectra	1052	1058
yielded	1060	1066
different	1068	1076
rate	1078	1081
constants	1083	1091
for	1093	1095
the	1097	1099
different	1101	1109
binding	1111	1117
sites	1119	1123
.	1124	1124

For	1126	1128
comparison	1130	1139
,	1140	1140
the	1142	1144
monomeric	1146	1154
lumazine	1156	1163
protein	1165	1171
was	1173	1175
investigated	1177	1188
as	1190	1191
an	1193	1194
example	1196	1202
of	1204	1205
a	1207	1207
case	1209	1212
with	1214	1217
simple	1219	1224
two	1226	1228
-	1229	1229
site	1230	1233
exchange	1235	1242
.	1243	1243

For	1245	1247
such	1249	1252
systems	1254	1260
,	1261	1261
all	1263	1265
kinetic	1267	1273
parameters	1275	1284
including	1286	1294
kon	1296	1298
and	1300	1302
the	1304	1306
dissociation	1308	1319
constant	1321	1328
can	1330	1332
be	1334	1335
determined	1337	1346
from	1348	1351
the	1353	1355
NOESY	1357	1361
spectrum	1363	1370
.	1371	1371

The	1373	1375
data	1377	1380
show	1382	1385
that	1387	1390
NMR	1392	1394
spectroscopy	1396	1407
can	1409	1411
produce	1413	1419
qualitative	1421	1431
and	1433	1435
quantitative	1437	1448
information	1450	1460
in	1462	1463
cases	1465	1469
of	1471	1472
nonequivalent	1474	1486
binding	1488	1494
sites	1496	1500
in	1502	1503
oligomeric	1505	1514
proteins	1516	1523
if	1525	1526
isolated	1528	1535
NMR	1537	1539
signals	1541	1547
of	1549	1550
the	1552	1554
different	1556	1564
forms	1566	1570
can	1572	1574
be	1576	1577
observed	1579	1586
.	1587	1587

The	1589	1591
technique	1593	1601
is	1603	1604
not	1606	1608
limited	1610	1616
to	1618	1619
19F	1621	1623
as	1625	1626
reporter	1628	1635
nucleus	1637	1643
.	1644	1644
